Articles tagged with Crohn Disease
Scientists identified a key gene, MDR1, governing toxin removal in the gut, which is linked to bowel disorders like Crohn's disease. Targeting vital cell parts with drugs can reverse damage and improve outcomes.
Recent clinical trials show biologics like infliximab and adalimumab promote 28-33% mucosal healing in Crohn's disease and ulcerative colitis. Researchers aim to develop new treatments targeting inflammation differently.
A study by Arizona State University and Mayo Clinic identified several unique biomarkers, called autoantibodies, that can accurately diagnose Crohn's disease. The discovery has the potential to provide early warning for those at risk of major illnesses, including cancer, autism, and diabetes.
A new study found that a strain of Saccharomyces cerevisiae can worsen intestinal damage in mouse models of colitis by causing elevated uric acid levels. Blocking this yeast strain may alleviate symptoms of inflammatory bowel disorders in some patients, according to the researchers.
A study published in Science Immunology reveals that a variant of the SP140 protein, an essential epigenetic reader protein, is lacking in patients with Crohn's disease. This deficiency triggers intestinal inflammation and impairs the immune system's response to microbial signals. The researchers found that patients with reduced SP140 ...
A new biosimilar called CT-P13 has been found safe and effective in treating Crohn's disease and ulcerative colitis, with a clinical response achieved in over 70% of patients at short-term follow-up. The treatment offers a cost-effective alternative to infliximab, a costly biologic therapy.
Grimes, assistant professor in UD's Department of Chemistry and Biochemistry, will use her fellowship to investigate how chronic inflammatory diseases, such as asthma and Crohn's disease, arise from bacterial cell wall fragments. Her work aims to understand the immune system's response to these molecules.
New research uncovers a connection between Crohn's disease and spondyloarthritis, finding that IgA-coated E. coli bacteria trigger inflammation in Th17 cells. This discovery may lead to the development of diagnostic tools and therapies targeting both conditions.
Pre-operative liquid feeding is associated with reduced post-operative abscesses and intestinal leakage by nine-fold, with only one of 38 patients developing these complications. This study suggests exclusive enteral nutrition as a bridge to safer semi-elective surgery for complicated Crohn's disease patients.
Researchers identified genetic variants that affect Crohn's disease severity, but found these variants do not determine individual risk of developing the condition. The study suggests new pathways for treating established disease.
Researchers developed a sensor that uses Raman spectroscopy to detect molecular markers of IBD in the colon, helping to distinguish between ulcerative colitis and Crohn's disease. The device could provide an objective gold standard for diagnosis and guide personalized treatment approaches.
Researchers at University of California San Diego School of Medicine found that ustekinumab induces response and remission in patients with Crohn's disease. The study showed high remission rates among patients treated with intravenous or subcutaneous ustekinumab.
Scientists have identified two distinct genetic subtypes in Crohn's disease patients, each with unique patterns of gene expression and clinical features. This discovery could lead to more effective treatment strategies tailored to individual patients' needs.
Researchers are exploring the connection between Johne's disease in cattle and Crohn's disease in humans. The study found that MAP-infected cows share symptoms with Crohn's patients, including thickened intestines, diarrhea, and low protein absorption.
Scientists at the University of British Columbia have made a groundbreaking discovery that could lead to treatments for fibrosis in Crohn's patients. Researchers found a mutation in mice that prevented fibrosis after infection, targeting a hormone receptor responsible for stimulating part of the immune response.
A UK-wide trial found that smokers with Crohn's disease are more likely to experience a recurrence after surgery. The study suggests that quitting smoking is crucial in preventing the condition from worsening.
Researchers at Case Western Reserve University aim to understand the role of intestinal innate immunity in Crohn's disease. They will investigate how mice develop experimental Crohn's disease and replicate these findings in humans, with the goal of developing new medications and treatments to cure the devastating ailment.
Researchers at Penn State College of Medicine developed a new care plan for managing septic perianal Crohn's disease, which combines medical and surgical treatments. The plan resulted in a 60% healing rate among patients, with half requiring permanent ostomy bags while the other half saw some improvement but did not heal completely.
Researchers discovered that genetic mutations in certain genes can impair the immune-enhancing effects of beneficial bacteria, leading to reduced efficacy of probiotic therapies in treating Crohn's disease. The study suggests a new potential cause for the disorder and may lead to advances in personalized medicine.
Researchers at Cedars-Sinai Medical Center discovered that genetic variants can prevent 'good' gut bacteria from functioning properly, contributing to the development of Crohn's disease. This study provides new insight into the interaction between genes and microorganisms in promoting health and preventing inflammation.
The specialty medical home approach aims to provide comprehensive, cost-effective care for patients with inflammatory bowel diseases. This model focuses on patient-centered care, social support, and mental health, addressing high rates of emotional difficulties and poor social support experienced by these patients.
A national research study will focus on the effectiveness of specific carbohydrate diets and Mediterranean-style diets to induce remission in patients with Crohn's disease. The study, led by Dr. James Lewis, aims to provide high-quality data and guidance for incorporating diet modifications into the treatment of the disease.
A new study by Hasbro Children's Hospital reveals Rhode Island has one of the highest rates of inflammatory bowel disease (IBD) in the US. The nationwide trend suggests a need for more research into IBD causes and targeted treatments.
Scientists designed a novel bispecific antibody that selectively blocks overproduction of TNF, a protein harmful when overproduced in autoimmune diseases. The prototype shows promise for treating conditions such as rheumatoid arthritis and Crohn's disease.
A study published in Gut journal found that oral and intravenous iron replacement therapies alter the gut microbiota significantly, particularly in Crohn's disease patients. These changes may lead to unstable bacterial ecosystems and increased risk of disease flares.
A clinical trial found that stem cell transplantation did not provide significant improvement in sustained disease remission after one year for patients with difficult-to-treat Crohn's disease. However, some patients showed objective signs of disease disappearance and discontinued active treatment more frequently in the stem cell group.
A study published in JAMA found that hematopoietic stem cell transplantation does not provide significant improvement for adults with difficult-to-treat Crohn's disease. The treatment was associated with increased toxicity, but no difference in sustained remission rates compared to conventional therapy.
A genetic study of 35,000 patients with inflammatory bowel disease (IBD) reveals new insights into disease progression and severity. The research suggests that IBD may be an array of bowel disorders, rather than a single condition, and could lead to more effective treatments if identified early.
A mindfulness-based group intervention significantly reduces anxiety, depression, and improves quality of life in patients with inflammatory bowel diseases. Six months later, the benefits persist, making mindfulness practices a feasible and effective treatment option.
A study of over 30,000 patients found that Crohn's disease and ulcerative colitis share similar genetic markers, suggesting a continuum of disorders. Genetic data can help identify misdiagnoses and inform treatment guidelines.
A study by researchers at the University of Pennsylvania School of Medicine found that different treatments for Crohn's disease in children have distinct effects on their gut microbiome. The use of antibiotics suppressed bacterial growth but facilitated fungal growth, while immunosuppressant medications reduced inflammation and bacteri...
A recent study found that diet-based and anti-inflammatory therapies alter different components of the microbial community without fully restoring the normal balance of gut bacteria and fungi in children with Crohn's disease. The treatment did not restore the normal balance of gut microbes, despite reducing inflammation.
A novel protein has been identified as a key player in preventing bowel inflammation, which is a major cause of Crohn's disease and ulcerative colitis. The discovery could lead to the development of targeted therapies for these conditions.
Researchers found that palmitic acid, a saturated fatty acid found in olive oil and meat, worsened inflammation in Crohn's disease. Omega-6 fatty acid, present in vegetable oils, actually reduced inflammation in the condition.
Dr. Theresa Alenghat receives $100,000 grant to study epigenetics role in IBD development and progression. Her research aims to test the hypothesis that dysregulation of epigenomic modifications and microbiota alterations drive IBD.
The study identified gene variants within three highly associated regions for Crohn's disease, including NOD2 and interleukin 23 receptor. Additionally, the researchers found novel regions of chromosomes 2 and 3 to be causative for IBD in African-Americans.
A recent study published in Cellular and Molecular Gastroenterology and Hepatology found that intra-abdominal fat cells may promote inflammation in IBD patients. The research isolated and cultured pre-intra-abdominal fat cells from healthy subjects and those with IBD, revealing significant differences in signaling mediators produced by...
The Crohn's & Colitis Foundation is establishing the world's largest database for Crohn's disease and ulcerative colitis research, which will integrate patient information, genetic profiles, and clinical data. The $17.5 million initiative aims to speed progress toward precision medicine and potential cures.
A study reveals that an unfavorable bacterial network configuration in the gut can cause inflammation similar to Crohn's disease. Researchers found that transplanting 'healthy' bacteria into patients' intestines may provide a conventional treatment option.
Women with inflammatory bowel disease (IBD) are at a higher risk of developing cervical dysplasia and cancer, according to a new study. Researchers found that patients with Crohn's disease had a significantly higher risk of cervical neoplasia, especially those diagnosed at a young age or treated with certain medications.
A recent study published in the IBD Journal found significant racial disparities in the treatment and outcomes of children with Crohn's disease. Black children had a 1.5 times higher frequency of hospital readmissions due to Crohn's disease compared to white children.
The Strategic Pharma-Academic Research Consortium (SPARC) has awarded over $1.9 million to advance research on autoimmune diseases such as multiple sclerosis, lupus, and Crohn's disease. The funded projects will focus on understanding the root causes of these conditions and developing new treatments.
Researchers found patients with Crohn's disease and ulcerative colitis had greater viral diversity than healthy volunteers, suggesting viruses play a role in the diseases. The study suggests that studying the virome may reveal new insights into obesity and diabetes.
Researchers found that cathelicidin protein can prevent intestinal fibrosis and scarring in colitis, potentially sparing patients from repeated surgeries. The study used pre-clinical models of disease and human colonic fibroblasts to demonstrate the anti-fibrotic effects of cathelicidin.
A new study found groups of genes linked to imbalanced gut microbes in patients with IBD, offering a step toward developing targeted treatments. The research also confirmed the impact of antibiotics on gut microbiome imbalance, highlighting the complex interplay between genetics and environment.
The American Gastroenterological Association has released a new clinical decision tool to guide gastroenterologists in assessing and treating patients with Crohn's disease. The tool synthesizes current literature to create a practical algorithm for clinicians, providing a pathway for better quality care.
A retrospective single-center study found that restarting infliximab therapy after a drug holiday is safe and effective for IBD patients. The average duration of infliximab holiday was 15 months. Patients who were in remission at the time infliximab was discontinued showed a 78 percent response rate at one year.
A population-based study found that IBD prevalence rose significantly in children under 18 and adults 18-64 years-old, while elderly patients saw a rise in prevalence despite stable new cases. The study highlights the growing burden of IBD on Ontario's healthcare system.
Researchers have identified chemical changes in DNA that could screen people for Crohn's disease and reveal possible targets for new treatments. These genetic changes can be detected in blood samples, opening the door to a simple test for the condition.
A new study has found a wide range of epigenetic changes in children with Crohn's disease, which may be related to key environmental exposures. The research suggests that these changes could have early implications for clinical management of the disease.
Crohn's and Colitis Canada funds 9 promising research projects exploring genetic, environmental causes, symptoms, and treatment options for these debilitating diseases. The organization aims to improve patient care and quality of life for over 233,000 Canadians affected by Crohn's and colitis.
Researchers at the University of Delaware have identified a protein called HSP70 that helps stabilize NOD2, a key protein involved in Crohn's disease. This finding provides a possible pathway for developing an effective therapy for the inflammatory bowel disease.
A new study in the Journal of Clinical Investigation identifies a specific gene expression profile and microbial community associated with Crohn's disease. Pediatric Crohn's disease patients exhibit altered expression of genes DUOX2 and APOA1, as well as a distinct microbial community.
A new study reveals a connection between necroptosis, a type of programmed cell death, and inflammatory diseases such as Crohn's disease, rheumatoid arthritis, and psoriasis. RIPK1 is identified as the molecule that regulates this process, allowing cells to choose whether to live or die.
Infectious disease specialists at Johns Hopkins Children's Center identified a protein called NOD2 that regulates the body's immune response to CMV. The findings offer a new explanation for severe CMV infections in patients with Crohn's disease and may lead to vaccine development.
A multi-institutional study found that newly diagnosed Crohn's disease patients have an imbalance in their intestinal microbial population, with increased levels of harmful bacteria and decreased levels of beneficial bacteria. This imbalance is associated with the development of symptoms and may be exacerbated by antibiotic use.
Researchers have identified specific bacteria that are abnormally increased or decreased when Crohn's disease develops, suggesting potential targets for treatment. The study used biopsies from over 1,700 patients to uncover how microbes contribute to the inflammatory cascade of Crohn's disease.
Researchers found a decrease in classical blood monocytes and an increase in CD14hiHLA-DRdim macrophages, which drive inflammation in the disease. This discovery may lead to new therapeutic targets for Crohn's disease treatment.
The REACT clinical trial found that an accelerated step-care approach can improve the management of Crohn's disease by inducing remission, reducing corticosteroid use, and healing intestinal ulcers. This new strategy involves early introduction of combined immunosuppression in high-risk patients.
Early use of biologic drugs in children with moderate to severe Crohn's disease achieves higher clinical remission rates and normal growth velocity compared to standard treatment. Researchers found that anti-TNF-α therapy is more effective at achieving remission than immunomodulatory drugs.